Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-109182
Filing Date
2025-11-12
Accepted
2025-11-12 16:02:52
Documents
79
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0262412-10q_oruka.htm   iXBRL 10-Q 1438257
2 CERTIFICATION ea026241201ex31-1_oruka.htm EX-31.1 10130
3 CERTIFICATION ea026241201ex31-2_oruka.htm EX-31.2 10209
4 CERTIFICATION ea026241201ex32-1_oruka.htm EX-32.1 6001
  Complete submission text file 0001213900-25-109182.txt   7560229

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE orka-20250930.xsd EX-101.SCH 72349
6 XBRL CALCULATION FILE orka-20250930_cal.xml EX-101.CAL 32439
7 XBRL DEFINITION FILE orka-20250930_def.xml EX-101.DEF 348729
8 XBRL LABEL FILE orka-20250930_lab.xml EX-101.LAB 599088
9 XBRL PRESENTATION FILE orka-20250930_pre.xml EX-101.PRE 372412
81 EXTRACTED XBRL INSTANCE DOCUMENT ea0262412-10q_oruka_htm.xml XML 1062198
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-22873 | Film No.: 251472491
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)